<DOC>
	<DOCNO>NCT00970281</DOCNO>
	<brief_summary>The primary objective study confirm efficacy intramuscular injection ( IM ) olanzapine 10 milligram ( mg ) patient exacerbation schizophrenia acute psychotic agitation great intramuscular placebo comparing change baseline 2 hour first IM injection agitation .</brief_summary>
	<brief_title>A Study Olanzapine Patients With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Patients meet Diagnostic Statistical Manual Mental Disorders Fourth Edition Text Revision ( DSMIVTR ) criterion schizophrenia . Patients exacerbation schizophrenia acute psychotic agitation . Patients hospitalize study . Patients , proxy consenters , understand nature study sign inform consent document . The investigator subinvestigator ( ) judge patient able cooperate protocol procedure . Patients consider agitation appropriate candidate treatment intramuscular ( IM ) medication investigator subinvestigator ( ) . The investigator subinvestigator ( ) believe safe administer IM olanzapine patient consideration safety , include anticholinergic action IM olanzapine . Patients score 1 2 AgitationCalmness Evaluation Scale ( ACES ) first IM injection investigational product . Patients whose Global Assessment Functioning ( GAF ) score less equal 40 within last 1 year inform consent . Patients defect . Patients whose agitation continue 2 week inform consent . Patients previously treat antipsychotic consider investigator subinvestigator ( ) treatmentresistant antipsychotic . Patients treat oral olanzapine dose 20 milligram ( mg ) 4 week improve . Patient history participation clozapine trial treatment clozapine . Patients comorbidity mental retardation personality disorder . Patients whose agitation possibly due brain lesion ( limit ) head injury , stroke , brain breeding , cerebral infection . Patients substupor stupor . One seizures without clear resolve etiology . However , patient one seizures past identifiable etiology , etiology resolve , patient may enter . Patients history DSMIVTR substance ( except caffeine nicotine ) abuse within past 30 day substance dependence within past 6 month inform consent . Or patient history use illegal drug . Patients whose agitation cause substance abuse neurologic condition , opinion investigator subinvestigator ( ) . Patients diagnosis Parkinson 's disease dementia . Patients actively suicidal ( high risk suicide attempt ) opinion investigator subinvestigator ( ) . Patients inadequately control diabetes , patient whose treatment diabetes change within 4 week first IM injection investigational product . The investigator 's discretion supersede even patient meet criterion concurrent diabetes . Patients receive haloperidol decanoate fluphenazine decanoate , fluphenazine enanthate within 8 week first IM injection investigational product . Patients receive risperidone longacting injection within 12 week first IM injection investigational product . Patients history receive injectable depot antipsychotic haloperidol decanoate , fluphenazine decanoate , fluphenazine enanthate risperidone longacting injection . Patients receive antipsychotic prohibit concomitant medicine within 2 hour first IM injection investigational product . Patients receive benzodiazepine within 4 hour first IM injection investigational product .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>